This is a partial excerpt of an article, also from

This is a partial excerpt of an article, also from medscape(the last sentence is the "punchline":
"... But since a French study found no difference in outcomes between patients treated with hydroxychloroquine or not, they no longer use it, nor do they use azithromycin, which initially they also felt might benefit COVID-19 recovery in these patients, Akalin explained.

Intriguingly, however, they did treat two patients with the interleukin-6 (IL-6) inhibitor tocilizumab (Actemra, Roche), while six others received the CCR5 inhibitor leronlimab (CytoDyn), both of which blunt high IL-6 levels characteristic of the cytokine storm that can occur in patients with moderate and severe COVID-19.

Before and after laboratory results indicated that leronlimab markedly reduced elevated IL-6 levels in five patients with high pretreatment levels, Akalin noted.


Moreover, while only eight patients in total received tocilizumab or leronlimab, all of these patients were all among the group who received mechanical ventilation and the mortality rate was 50% in this small group, lower than that seen among intubated patients with COVID-19 in the general population, he noted."